Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture.
null nullRobert V O'TooleDeborah M SteinNathan N O'HaraKatherine P FreyTara J TaylorDaniel O ScharfsteinAnthony R CarliniKuladeep SudiniYasmin DeganiGerard P SlobogeanElliott R HautWilliam ObremskeyReza FiroozabadiMichael J BosseSamuel Z GoldhaberDebra MarvelRenan C CastilloPublished in: The New England journal of medicine (2023)
In patients with extremity fractures that had been treated operatively or with any pelvic or acetabular fracture, thromboprophylaxis with aspirin was noninferior to low-molecular-weight heparin in preventing death and was associated with low incidences of deep-vein thrombosis and pulmonary embolism and low 90-day mortality. (Funded by the Patient-Centered Outcomes Research Institute; PREVENT CLOT ClinicalTrials.gov number, NCT02984384.).
Keyphrases
- pulmonary embolism
- venous thromboembolism
- cardiovascular events
- low dose
- direct oral anticoagulants
- inferior vena cava
- growth factor
- antiplatelet therapy
- coronary artery disease
- hip fracture
- rectal cancer
- cardiovascular disease
- risk factors
- type diabetes
- atrial fibrillation
- glycemic control
- total knee arthroplasty
- insulin resistance